ArticleFrontiers in oncology2022

KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population.

Sara Fancelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.